MISTER SPEX SE (MRX.DE) Fundamental Analysis & Valuation

FRA:MRX • DE000A3CSAE2

Current stock price

1.315 EUR
+0.06 (+5.2%)
Last:

This MRX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MRX.DE Profitability Analysis

1.1 Basic Checks

  • In the past year MRX has reported negative net income.
  • In the past year MRX had a positive cash flow from operations.
  • MRX had negative earnings in each of the past 5 years.
  • In multiple years MRX reported negative operating cash flow during the last 5 years.
MRX.DE Yearly Net Income VS EBIT VS OCF VS FCFMRX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M

1.2 Ratios

  • With a Return On Assets value of -19.52%, MRX is not doing good in the industry: 87.76% of the companies in the same industry are doing better.
  • The Return On Equity of MRX (-61.04%) is worse than 79.59% of its industry peers.
Industry RankSector Rank
ROA -19.52%
ROE -61.04%
ROIC N/A
ROA(3y)-28.71%
ROA(5y)-22.23%
ROE(3y)-69.99%
ROE(5y)-49.04%
ROIC(3y)N/A
ROIC(5y)N/A
MRX.DE Yearly ROA, ROE, ROICMRX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • With an excellent Gross Margin value of 55.83%, MRX belongs to the best of the industry, outperforming 81.63% of the companies in the same industry.
  • MRX's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y1.4%
MRX.DE Yearly Profit, Operating, Gross MarginsMRX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. MRX.DE Health Analysis

2.1 Basic Checks

  • MRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MRX has more shares outstanding
  • MRX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MRX is higher compared to a year ago.
MRX.DE Yearly Shares OutstandingMRX.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
MRX.DE Yearly Total Debt VS Total AssetsMRX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MRX has an Altman-Z score of -1.79. This is a bad value and indicates that MRX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -1.79, MRX is not doing good in the industry: 77.55% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 1.02 is on the high side and indicates that MRX has dependencies on debt financing.
  • MRX has a worse Debt to Equity ratio (1.02) than 65.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF N/A
Altman-Z -1.79
ROIC/WACCN/A
WACC5.23%
MRX.DE Yearly LT Debt VS Equity VS FCFMRX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

2.3 Liquidity

  • MRX has a Current Ratio of 1.97. This is a normal value and indicates that MRX is financially healthy and should not expect problems in meeting its short term obligations.
  • MRX's Current ratio of 1.97 is amongst the best of the industry. MRX outperforms 81.63% of its industry peers.
  • MRX has a Quick Ratio of 1.44. This is a normal value and indicates that MRX is financially healthy and should not expect problems in meeting its short term obligations.
  • MRX's Quick ratio of 1.44 is amongst the best of the industry. MRX outperforms 89.80% of its industry peers.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.44
MRX.DE Yearly Current Assets VS Current LiabilitesMRX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. MRX.DE Growth Analysis

3.1 Past

  • MRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.84%, which is quite impressive.
  • The Revenue for MRX has decreased by -16.28% in the past year. This is quite bad
  • The Revenue has been growing slightly by 2.02% on average over the past years.
EPS 1Y (TTM)66.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.51%
Revenue 1Y (TTM)-16.28%
Revenue growth 3Y-4.76%
Revenue growth 5Y2.02%
Sales Q2Q%-9.68%

3.2 Future

  • The Earnings Per Share is expected to grow by 20.10% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, MRX will show a small growth in Revenue. The Revenue will grow by 2.24% on average per year.
EPS Next Y9.36%
EPS Next 2Y19.55%
EPS Next 3Y20.1%
EPS Next 5YN/A
Revenue Next Year-5.56%
Revenue Next 2Y-1.64%
Revenue Next 3Y2.01%
Revenue Next 5Y2.24%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MRX.DE Yearly Revenue VS EstimatesMRX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
MRX.DE Yearly EPS VS EstimatesMRX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. MRX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • MRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRX.DE Price Earnings VS Forward Price EarningsMRX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRX.DE Per share dataMRX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • MRX's earnings are expected to grow with 20.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.55%
EPS Next 3Y20.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRX.DE Dividend Analysis

5.1 Amount

  • No dividends for MRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRX.DE Fundamentals: All Metrics, Ratios and Statistics

MISTER SPEX SE

FRA:MRX (4/29/2026, 7:00:00 PM)

1.315

+0.06 (+5.2%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Industry Strength25
Industry Growth92.67
Earnings (Last)11-13
Earnings (Next)N/A
Inst Owners19.55%
Inst Owner ChangeN/A
Ins Owners25.44%
Ins Owner ChangeN/A
Market Cap46.09M
Revenue(TTM)181.46M
Net Income(TTM)-28.17M
Analysts75
Price Target3.21 (144.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.62%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)4.21%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-22.22%
PT rev (3m)-27.25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-49.72%
EPS NY rev (3m)-61.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-6.31%
Revenue NY rev (3m)-11.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.25
P/FCF N/A
P/OCF 29.81
P/B 1
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0.04
OCFY3.35%
SpS5.18
BVpS1.32
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -19.52%
ROE -61.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.83%
FCFM N/A
ROA(3y)-28.71%
ROA(5y)-22.23%
ROE(3y)-69.99%
ROE(5y)-49.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y1.4%
F-Score5
Asset Turnover1.26
Health
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.52%
Cap/Sales 1.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.44
Altman-Z -1.79
F-Score5
WACC5.23%
ROIC/WACCN/A
Cap/Depr(3y)21.93%
Cap/Depr(5y)48.21%
Cap/Sales(3y)3.7%
Cap/Sales(5y)5.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.51%
EPS Next Y9.36%
EPS Next 2Y19.55%
EPS Next 3Y20.1%
EPS Next 5YN/A
Revenue 1Y (TTM)-16.28%
Revenue growth 3Y-4.76%
Revenue growth 5Y2.02%
Sales Q2Q%-9.68%
Revenue Next Year-5.56%
Revenue Next 2Y-1.64%
Revenue Next 3Y2.01%
Revenue Next 5Y2.24%
EBIT growth 1Y69.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year166.35%
EBIT Next 3Y36.14%
EBIT Next 5Y20.9%
FCF growth 1Y93.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y109.49%
OCF growth 3YN/A
OCF growth 5YN/A

MISTER SPEX SE / MRX.DE Fundamental Analysis FAQ

What is the fundamental rating for MRX stock?

ChartMill assigns a fundamental rating of 2 / 10 to MRX.DE.


What is the valuation status for MRX stock?

ChartMill assigns a valuation rating of 1 / 10 to MISTER SPEX SE (MRX.DE). This can be considered as Overvalued.


What is the profitability of MRX stock?

MISTER SPEX SE (MRX.DE) has a profitability rating of 2 / 10.


What is the financial health of MISTER SPEX SE (MRX.DE) stock?

The financial health rating of MISTER SPEX SE (MRX.DE) is 2 / 10.